Abstracts tagged "treatment options and ultrasonography"

Abstract Number: 1973 • 2016 ACR/ARHP Annual Meeting
Intramuscular Versus Ultrasound Guided Peritendinous Glucocorticoid Injection for Tenosynovitis in Patients with Rheumatoid Arthritis – a Randomised, Double-Blind, Controlled Study
Mads Ammitzbøll-Danielsen^1,2, Mikkel Ostergaard^2,3, Viktoria Fana⁴, Daniel Glinatsi^2,5, Uffe Møller Døhn⁶, Lykke Midtbøll Ørnbjerg⁷, Esperanza Naredo⁸ and Lene Terslev⁶, ¹Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Rigshospitalet , Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁵Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁸Rheumatology, Hospital General Universitario Gregorio Marañón and Universidad Complutense, Madrid, Spain
Background/Purpose: The aim of this study was to compare the efficacy of intramuscular versus ultrasound (US)-guided peritendinous glucocorticoid injection in providing disease control after…
Abstract Number: L14 • 2014 ACR/ARHP Annual Meeting
Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound
Miroslav Harjacek¹, Mandica Vidovic², Lovro Lamot^2,3, Marija Perica² and Lana Tambic Bukovac², ¹Rheumatology, Children's Hospital Srebrnjak, Zagreb, Croatia, ²Children's Hospital Srebrnjak, Zagreb, Croatia, ³University of Zagreb School of Medicine, Zagreb, Croatia
Background/Purpose: Intra-articular (IA) infliximab (IFX) is an attractive treatment option of chronic arthritis, but based on few heterogenic studies, outcome is still controversial. To investigate…
Abstract Number: 2686 • 2013 ACR/ARHP Annual Meeting
Impact of Methotrexate Dose Reduction Upon Initiation of Adalimumab On Clinical and Ultrasonographic Parameters in Patients With Moderate to Severe Rheumatoid Arthritis
Gurjit S. Kaeley¹, Amy M. Evangelisto², Midori Jane Nishio³, Shufang Liu⁴ and Hartmut Kupper⁵, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Arthritis, Rheumatic and Back Disease Associates, Voorhees, NJ, ³Diablo Clinical Research, Walnut Creek, CA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Methotrexate (MTX) is the recommended first-line disease-modifying antirheumatic drug (DMARD) for the treatment of moderately to severely active rheumatoid arthritis (RA). Whether patients (pts)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].